

Jan Damoiseaux\*, Ingmar Heijnen, Christel Van Campenhout, Catharina Eriksson, Nicole Fabien, Manfred Herold, Renate G. van der Molen, William Egner, Dina Patel, Aresio Plaza-Lopez, Antonella Radice, Marie José Rego de Sousa, Markku Viander and Yehuda Shoenfeld

# An international survey on anti-neutrophil cytoplasmic antibodies (ANCA) testing in daily clinical practice

DOI 10.1515/cclm-2017-0306

Received April 7, 2017; accepted May 29, 2017

## Abstract

**Background:** Detection of anti-neutrophil cytoplasmic antibodies (ANCA) is important for the diagnosis of the ANCA-associated vasculitides (AAV). For AAV, especially ANCA directed against myeloperoxidase (MPO) and proteinase 3 (PR3) are most relevant. ANCA with less well-defined specificities may, however, also be detected in other inflammatory and non-inflammatory conditions.

**Methods:** A questionnaire, initiated by the European Autoimmunity Standardisation Initiative (EASI), was used to gather information on methods and testing algorithms used for ANCA in clinical laboratories of 12 European countries (EASI survey).

**Results:** Four hundred and twenty-nine responses were included in the EASI survey analysis which revealed differences within countries and between countries. Laboratories overall were poor in adherence to international consensus on ANCA testing. Substantial variation was observed with respect to the use of ANCA indirect immunofluorescence (IIF) in the algorithm, application of distinct

methods for MPO- and PR3-ANCA, the daily availability of new ANCA results, and interpretation of test results.

**Conclusions:** Awareness of these differences may stimulate further harmonization and standardization of ANCA testing. This may be promoted by an update of the international ANCA consensus and the introduction of international standards.

**Keywords:** ANCA; myeloperoxidase; proteinase-3; testing algorithm; vasculitis.

## Introduction

Laboratory tests for anti-neutrophil cytoplasmic antibodies (ANCA) are used to diagnose and monitor inflammatory activity of the primary systemic small vessel vasculitides, further referred to as ANCA-associated vasculitis (AAV) [1–3]. According to the international consensus statement on testing and reporting of ANCA “ANCA is best demonstrated in AAV by using a combination of indirect immunofluorescence (IIF) on ethanol-fixed neutrophils and enzyme-linked immunosorbent assays (ELISAs) that

\*Corresponding author: Jan Damoiseaux, PhD, Central Diagnostic Laboratory, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands, E-mail: jan.damoiseaux@mumc.nl

Ingmar Heijnen: Medical Immunology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland

Christel Van Campenhout: Quality of Medical Laboratories, Scientific Institute of Public Health, Brussels, Belgium

Catharina Eriksson: Department of Clinical Immunology/Microbiology, Umeå University, Umeå, Sweden

Nicole Fabien: Department of Immunology, UF Autoimmunity, Hospices Civils de Lyon, CHLS, Pierre-Benite, France

Manfred Herold: Department of Internal Medicine/Rheumatology unit, Innsbruck Medical University, Innsbruck, Austria

Renate G. van der Molen: Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud University Medical Center, Nijmegen, The Netherlands

William Egner and Dina Patel: UK NEQAS Immunology, Immunochemistry and Allergy, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

Aresio Plaza-Lopez: Department of Immunology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain

Antonella Radice: Microbiology Institute, San Carlo Borromeo Hospital, Milan, Italy – on behalf of the Italian Forum on Autoimmune Disease Research (FIRMA)

Marie José Rego de Sousa: Immunopathology and Autoimmunity Department, Centro de Medicina Laboratorial Germano de Sousa, Lisbon, Portugal

Markku Viander: Department of Medical Microbiology and Immunology, University of Turku, Turku, Finland

Yehuda Shoenfeld: Zabudowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

detect ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO)” [4]. This consensus advocates that serum samples from all new patients with an ANCA request should initially be tested by IIF. Positivity of IIF (i.e. a C-ANCA or P-ANCA fluorescence pattern) in combination with a positive test for PR3- or MPO-ANCA, respectively, is highly specific for AAV [5].

However, ANCA detected by IIF that do not react with PR3 or MPO have been described in many inflammatory and non-inflammatory conditions, such as autoimmune diseases of the gastro-intestinal tract [6, 7] and liver [8], as well as autoimmune rheumatic diseases, infectious diseases and adverse drug reaction [9]. Although the clinical relevance of ANCA detection in these non-AAV conditions is limited, several approaches have been evaluated to increase this relevance. These include the use of alternative IIF fixatives, such as formalin and methanol, and immunoassays for other target antigens, such as elastase and lactoferrin. Altogether, the autoantigens recognized by ANCA in non-AAV remain ill-defined and there is no international consensus on their place in diagnostic algorithms. According to the addendum to the international consensus [10], detection of ANCA against such antigens is not recommended in non-AAV, and – in addition – the use of IIF fixatives other than ethanol is not advocated for routine ANCA testing in case of these clinical conditions.

Since the publication of the international consensus on ANCA testing in 1999 many new detection technologies have become available. These include second (capture technology) and third (anchor technology) generation ELISAs [11–15], but also alternative antigen-specific assays, like addressable laser bead immune-assays (ALBIA) [16–18], chemiluminescent immune-assays (CLIA) [19], fluorescent-enzyme immune-assays (FEIA) [20, 21], dot and line immuno-assays (DIA/LIA) [22], and even IIF [23, 24]. On the one hand, the place of these new techniques in the international consensus testing algorithm is not established and may require revision [25, 26], while on the other hand, the diversification of ANCA test methods may be an additional hurdle for standardization of these assays.

The diversity of the available ANCA IIF substrates, antigen-specific assays and technologies, and variety of test algorithms may result in highly diverse ANCA testing procedures in clinical laboratories which, eventually, may cause variation in outcomes for patients. Therefore, although consensus guidelines have been available for over 15 years, we here aim to evaluate adherence to existing guidance in diagnostic laboratories internationally, in order to identify and address any issues with harmonization. As such, this European Autoimmunity Standardisation Initiative (EASI) study addresses the EASI

aspirations for “standardization of methodology, tests, and interpretation of results” and “harmonization of test algorithms” [27].

## Materials and methods

A questionnaire on ANCA testing was first developed for Dutch clinical laboratories by Renate van der Molen (Radboud University Medical Center, Nijmegen), Caroline Roozendaal (University Medical Center Groningen), and Jan Damoiseaux (Maastricht University Medical Center). This questionnaire was distributed to all Dutch laboratories participating in the external quality assessment for ANCA [28]. Next, the questionnaire was translated to English and distributed by national EASI-teams in 11 other European countries. In the UK and Ireland the questionnaire was distributed in collaboration with UK NEQAS. In most countries (Austria, Belgium, Finland, France, Ireland, the Netherlands, Spain, UK) the questionnaire was distributed only to laboratories that were involved in ANCA testing, while in some other countries either all laboratories were contacted without previous knowledge or certainty if ANCA-tests were being performed (Portugal, Sweden, Switzerland), or laboratory specialists known to be potentially involved in ANCA testing were selected (Italy).

In total, the questionnaire consisted of 54 questions in five categories: laboratory organization (n=5), ANCA IIF testing (n=16), ANCA specificity testing (n=11), the algorithm for ANCA testing (n=16), and ANCA testing with short turn-around-time (STAT; n=6). STAT testing was defined as having results available within 24 h. Data of the participating countries, further referred to as EASI survey, were collected by the national EASI-teams or UK NEQAS. These data were summarized in a standard Excel-file and sent to the coordinator of the study (JD). Since the results of the UK and Ireland were compiled in a single dataset, the results were also combined in the analyses.

The results are reported as absolute numbers, i.e. the number of laboratories, and percentages of either (A) the total number of responding laboratories that perform ANCA testing, or (B) to a subgroup of analysis, as indicated in the text. Non-responders were excluded from the total denominator for each question. Ethical approval: the conducted research is not related to either human or animals use.

## Results

### Response on questionnaire and ANCA workload of participating laboratories

The data on response and type of participating laboratories per country are summarized in Table 1. In total, the questionnaire was distributed among 628 laboratories in 11 European countries (Italy excluded). In total, 328 laboratories (52.2%) responded. In Sweden (n=3) and Switzerland (n=8) some laboratories responded that they do not perform ANCA tests; these responses were

**Table 1:** Response on questionnaire and type of participating laboratory per country.

	Austria	Belgium	Finland	France	Italy	Netherlands	Portugal	Spain	Sweden	Switzerland	UK and Ireland
Laboratories <sup>a</sup>	16	84	5	62	300 <sup>e</sup>	50	194	55	22	44	96
Participation <sup>b</sup>	16 (100%)	72 (85.7%)	4 (80%)	36 (58.1%)	145 (48.3%) 112 (37.3%) <sup>e</sup>	43 (86%)	34 (17.5%)	20 (36.4%)	14 (63.6%) 11 (50%) <sup>e</sup>	29 (65.9%) 21 (47.7%) <sup>e</sup>	60 (62.5%)
Organization <sup>c</sup>											
University	3 (18.8%)	7 (9.7%)	4 (100%)	25 (69.4%)	16 (14.7%)	8 (18.6%)	7 (20.6%)	17 (85.0%)	5 (45.5%)	6 (28.6%)	–
Non-university	9 (56.3%)	51 (70.8%)	–	6 (16.7%)	86 (78.9%)	31 (72.1%)	16 (47.1%)	3 (15.0%)	5 (45.5%)	8 (38.1%)	51 (87.9%) <sup>e</sup>
Private	4 (25.0%)	14 (19.4%)	–	4 (11.1%)	7 (6.4%)	4 (9.3%)	11 (32.4%)	–	1 (9.1%)	7 (33.3%)	3 (5.2%)
Other	–	–	–	1 (2.8%)	–	–	–	–	–	–	4 (6.9%)
# ANCA requests <sup>d</sup>											
<5	–	10 (13.9%)	–	2 (5.6%)	15 (13.8%)	2 (4.7%)	7 (20.6%)	1 (5.0%)	–	2 (9.5%)	1 (1.7%)
5–15	1 (6.3%)	21 (29.2%)	–	6 (16.7%)	43 (39.4%)	15 (34.9%)	8 (23.5%)	2 (10.0%)	3 (27.3%)	3 (14.3%)	2 (3.4%)
15–30	5 (31.3%)	18 (25.0%)	–	6 (16.7%)	24 (22.0%)	16 (37.2%)	2 (5.9%)	5 (25.0%)	2 (18.2%)	3 (14.3%)	8 (13.8%)
30–50	4 (25.0%)	13 (18.1%)	1 (25%)	11 (30.6%)	17 (15.6%)	7 (16.3%)	5 (14.7%)	8 (40.0%)	3 (27.3%)	6 (28.6%)	8 (13.8%)
>50	6 (37.5%)	9 (12.5%)	3 (75%)	11 (30.6%)	10 (9.2%)	3 (7.0%)	9 (26.5%)	4 (20.0%)	3 (27.3%)	6 (28.6%)	39 (67.2%)

<sup>a</sup>Number of laboratories that were addressed (in Italy<sup>e</sup> this refers to number of laboratory specialists). <sup>b</sup>Number of laboratories that responded (percentage of laboratories that were addressed); in Italy<sup>e</sup> 33 responses were excluded as being incomplete, contradicting or duplicate responses from the Italian laboratory specialists, while in Sweden<sup>e</sup> and Switzerland<sup>e</sup> three and eight laboratories responded that they do not perform ANCA tests, respectively. <sup>c</sup>Number of laboratories (percentage of responding laboratories that perform ANCA tests); non-university refers to laboratories within hospitals (public or private) not directly associated with a medical university, private refers to laboratories not directly associated with a hospital. In the UK<sup>e</sup> no distinction is made between public hospital laboratories which have University or NHS employers, although most major hospitals are associated with a University. <sup>d</sup>Number of ANCA requests per week (percentage of responding laboratories that perform ANCA tests).

excluded from further analyses. In Italy, the questionnaire was distributed to laboratory specialists supposed to be involved in ANCA testing ( $n=300$ ). In total, 145 Italian laboratory specialists (48.3%) responded. Thirty-three Italian responses were not included because some laboratory specialists answered only a few questions, some reported contrasting results, and some responded twice. Altogether, 429 responses were included in the analyses (Figure 1).

The workload of laboratories was very variable. In Finland a relatively large weekly number of ANCA requests are reported by the large university laboratories. Many of the participating laboratories in the UK/Ireland ( $n=39$ ; 67.2%) also received high numbers ( $>50$ ) of weekly ANCA requests (Table 1). In Belgium ( $n=31$ ; 43.1%), Italy ( $n=58$ ; 43.2%), the Netherlands ( $n=17$ ; 39.6%), and Portugal

( $n=15$ ; 44.1%) many participating laboratories reported a relatively low number ( $\leq 15$ ) of weekly ANCA requests.

### ANCA testing by indirect immunofluorescence


Three hundred and thirty-four of the 429 responding laboratories (77.9%) performed ANCA IIF on ethanol-fixed neutrophils (Table 2). This is not the case in  $>20\%$  of the participating laboratories in Austria ( $n=8$ ; 50.0%), Italy ( $n=27$ ; 25.0%), the Netherlands ( $n=9$ ; 20.9%), Portugal ( $n=16$ ; 47.1%), and Sweden ( $n=7$ ; 63.6%). In total 221 laboratories (66.2% of laboratories that use ANCA IIF) also perform ANCA on formalin-fixed neutrophils. Particularly in Sweden ( $n=0$ ; 0%) and UK/Ireland (14.9%) formalin-fixed slides are not or hardly used at all. The majority of the laboratories ( $n=122$ ; 55.2%) that additionally perform ANCA IIF on formalin-fixed slides use this strategy for all ANCA requests. Most of the other laboratories ( $n=83$ ; 37.6%) restrict this to samples that are positive on ethanol-fixed slides (either all positives or pattern dependent). Of the remaining 17 laboratories few laboratories ( $n=5$ ) utilize formalin-fixed slides only for requests for gastroenterologic diseases and the other laboratories ( $n=12$ ) for miscellaneous reasons (not specified in the questionnaires).

As recommended at the First International ANCA Workshop [29], the majority of the participating laboratories used 1:20 serum dilution for ANCA IIF screening. In the Netherlands a 1:16 screening dilution is used by 7 laboratories (20.6%). Only half of the EASI survey responding laboratories consistently perform titrations ( $n=165$ ; 50.0%). However, this appeared very heterogeneous in the different European countries, varying from  $<25\%$  in Spain ( $n=4$ ; 20%) and UK/Ireland ( $n=12$ ; 23.5%) to 100% in Austria ( $n=8$ ) and Finland ( $n=4$ ).

Distinction of ANCA IIF patterns, on the other hand, is consistently performed by nearly all participating laboratories that perform ANCA IIF testing ( $n=321$ ; 96.1%). Basically all these laboratories report C-ANCA and P-ANCA patterns, while about 80% and 15% of the laboratories report atypical ANCA and other ANCA patterns, respectively. The definitions used for P-ANCA and atypical ANCA, however, are very diverse (Table 3).

### Antigen-specific ANCA testing

According to the international consensus on ANCA testing, specificity for MPO and PR3 should be tested by



**Figure 1:** Schematic overview of questionnaire distribution, response, inclusion and analysis.

<sup>1</sup>Initially, Italy was excluded from the data of the EASI survey, because <sup>2</sup>Italy addressed laboratory specialists instead of laboratories. Finally, the results were combined for analysis in the total EASI survey. <sup>3</sup>Exclusion is based on ANCA testing not being performed in the respective laboratories, <sup>4</sup>or based on incomplete, contradicting, or duplicate responses from Italian laboratory specialists.

Table 2: ANCA detection by indirect immunofluorescence.

	Austria	Belgium	Finland	France	Italy	Netherlands	Portugal	Spain	Sweden	Switzerland	UK and Ireland
ANCA IIF (EtOH) <sup>a</sup>	8 (50.0%)	60 (83.3%)	4 (100%)	35 (97.2%)	81 (75.0%)	34 (79.1%)	18 (52.9%)	20 (100%)	4 (36.4%)	19 (90.5%)	51 (86.4%)
ANCA IIF (Form) <sup>b</sup>	8 (100%)	50 (83.3%)	2 (50%)	23 (65.7%)	59 (72.8%)	23 (67.6%)	15 (83.3%)	17 (85.0%)	0 (0%)	17 (89.5%)	7 (13.7%)
Screening dilution <sup>c</sup>											
1/10	2 (25.0%)	9 (15.0%)	-	4 (11.4%)	29 (37.7%)	5 (14.7%)	7 (38.9%)	4 (20.0%)	-	1 (5.3%)	7 (13.7%)
1/16	-	-	-	-	-	7 (20.6%)	-	-	-	-	-
1/20	5 (62.5%)	31 (51.7%)	4 (100%)	25 (71.4%)	46 (59.7%)	18 (52.9%)	10 (55.6%)	14 (70.0%)	2 (50.0%)	12 (63.2%)	32 (62.7%)
1/40	1 (12.5%)	20 (33.3%)	-	3 (8.6%)	-	4 (11.8%)	1 (5.6%)	2 (10.0%)	-	6 (31.6%)	9 (17.6%)
Titration <sup>c</sup>	8 (100%)	40 (66.7%)	4 (100%)	23 (65.7%)	30 (39.0%)	19 (55.9%)	7 (38.9%)	4 (20.0%)	2 (50.0%)	16 (84.2%)	12 (23.5%)
Pattern typing <sup>c</sup>	8 (100%)	60 (100%)	4 (100%)	34 (97.1%)	73 (94.8%)	32 (94.1%)	18 (100%)	19 (95.0%)	4 (100%)	19 (100%)	50 (98.0%)

<sup>a</sup>Number of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils (percentage of laboratories that responded). <sup>b</sup>Number of laboratories that perform ANCA by IIF on formalin-fixed neutrophils (percentage of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils). <sup>c</sup>Number of laboratories (percentage of laboratories that perform ANCA by IIF on ethanol-fixed neutrophils); in case of the screening dilution percentages may not add-up to 100% because some laboratories use other starting dilutions for ANCA screening.

ELISA [4]. In recent years, many different ELISA methods as well as alternative immuno-assays have become available. The assays used for detection of MPO- and PR3-ANCA in the different countries are summarized in Figure 2. In general, individual laboratories used the same method for MPO- and PR3-ANCA. Capture ELISAs, however, were slightly more prevalent for detection of PR3-ANCA than MPO-ANCA in Belgium, the Netherlands, Spain, and Switzerland. In Portugal some participating laboratories (n = 5; 14.7%) reported that they do not perform antigen-specific assays. In general, these laboratories use an external laboratory for antigen-specific ANCA testing.

Some technologies are remarkably linked to specific countries: ALBIA is very prevalent in French laboratories (n = 10; 27.8%), DIA/LIA are particularly used in Belgium (n = 16; 22.2%) and France (n = 6; 16.7%), while the category “other” in Italy (n = 22; 22.2%) is predominantly represented by CLIA. The majority of the participating laboratories report MPO- and PR3-ANCA in a quantitative way (82.1%). This ranges from 68.8% (n = 11; Austria) and 69.6% (n = 48; Belgium) to 100% (n = 4; Finland).

Besides testing for MPO- and PR3-ANCA, laboratories may also offer the possibility to analyze if autoantibodies to other ANCA specificities (azurocidin, bactericidal/permeability increasing protein, cathepsin G, elastase, lactoferrin, lysozyme, etc.) are present in a patient. These kind of tests are available in a minority of the laboratories participating in the EASI survey (n = 50; 13.0%).

### ANCA testing algorithm

Analysis of the responses about the ANCA testing algorithm is provided in Figure 3A. Overall, about half of the laboratories (n = 202; 53.2%), follow the minimal requirements of the international consensus, i.e. screening by IIF and if positive antigen-specific immuno-assays for both MPO- and PR3-ANCA [4]. A minority of laboratories (n = 22; 5.8%) only test for either MPO- or PR3-ANCA, based on the staining pattern observed in IIF. The optimal consensus algorithm [4], both IIF and antigen-specific immuno-assays on all samples, is executed in only 16.8% of the laboratories (n = 64). As noted above, about 20% of the participating laboratories do not use IIF in their algorithm. A minority of laboratories (n = 17; 4.5%) have reversed the sequence of testing compared to the international consensus: they screen by antigen-specific immuno-assays and perform IIF only on the positive samples. Significant heterogeneity in testing algorithms within and between European countries is evident in Figure 3A. Only in Finland (n = 4) the testing algorithm is completely harmonized in

**Table 3:** Definitions of ANCA patterns.**P-ANCA**

Consensus:<sup>a</sup> perinuclear fluorescence, with or without nuclear extension

Alternatives:<sup>b</sup>

- Perinuclear fluorescence with nuclear extension on ethanol-fixed neutrophils (i.e. excluding X-ANCA)
- Perinuclear fluorescence, with or without nuclear extension on ethanol-fixed neutrophils and MPO-ANCA in antigen-specific immunoassay
- Perinuclear fluorescence, with or without nuclear extension on ethanol-fixed neutrophils and classic granular cytoplasmic fluorescence with central or interlobular accentuation on formalin-fixed neutrophils
- Perinuclear fluorescence, with or without nuclear extension on ethanol-fixed neutrophils, classic granular cytoplasmic fluorescence with central or interlobular accentuation on formalin-fixed neutrophils, and MPO-ANCA in antigen-specific immunoassays


**Atypical ANCA**

Consensus:<sup>a</sup> all neutrophil-specific IIF reactivity other than C-ANCA, atypical C-ANCA, or P-ANCA; most commonly a combination of cytoplasmic and perinuclear fluorescence

Alternatives:<sup>b</sup>

- Perinuclear fluorescence without nuclear extension on ethanol-fixed neutrophils (also referred to as X-ANCA)
- Perinuclear fluorescence, with or without nuclear extension on ethanol-fixed neutrophils and negative on formalin-fixed neutrophils
- Any neutrophil-specific IIF reactivity on ethanol-fixed neutrophils and negative on formalin-fixed neutrophils
- Any neutrophil-specific IIF reactivity that is not confirmed as MPO- and/or PR3-ANCA in antigen-specific immunoassays
- Diffuse homogeneous cytoplasmic fluorescence without typical interlobular accentuation on ethanol-fixed neutrophils (i.e. consensus definition of atypical C-ANCA)
- Antinuclear antibody reactivity

<sup>a</sup>Consensus patterns are defined on IIF reactivity on ethanol-fixed neutrophils. <sup>b</sup>Only most prevalent alternatives are listed. In some countries also reactivity on methanol-fixed neutrophils is included in the definition. In general, antinuclear antibody interference is to be excluded.




**Figure 2:** Methods used for the detection of MPO-ANCA (A) and PR3-ANCA (B) as reported by the participating laboratories in different European countries.

Note that laboratories may use more than one method for antigen-specific ANCA detection; therefore total percentage may exceed 100%.

the participating laboratories, i.e. they all use the optimal consensus algorithm.

As AAV patients benefit from an early diagnosis, we surveyed rapid reporting (STAT) of ANCA testing, defined as having results available within 24 h of requesting. The majority of laboratories recognized both pulmonary alveolar hemorrhage and rapidly progressive glomerulonephritis as the most relevant clinical manifestation warranting STAT ANCA testing. However, one third ( $n=125$ ; 30.7%) of the laboratories participating in the EASI-survey do not offer such STAT ANCA testing (Figure 3B). This is most apparent in Austria ( $n=8$ ; 50.0%), Belgium ( $n=32$ ; 44.4%), Italy ( $n=46$ ; 56.1%), and Portugal ( $n=22$ ; 64.7%). In addition, many laboratories ( $n=158$ ; 38.8%) do not offer this STAT service during the weekend. This is explicitly the case in Finland ( $n=3$ ; 75.0%), France ( $n=32$ ; 88.9%), and Spain ( $n=15$ ; 75.0%). Only 13% ( $n=53$ ) of EASI-survey respondents offered rapid testing including the weekend. All laboratories that offer STAT testing use antigen-specific immuno-assays for both MPO- and PR3-ANCA. In the laboratories participating in the EASI survey about half of the laboratories additionally test by IIF ( $n=122$ ; 57.8%) and for anti-glomerular basement membrane (GBM) antibodies ( $n=115$ ; 54.5%).

If a patient is diagnosed as suffering from AAV, follow-up testing is to be performed with the ANCA specificity that was originally positive. The assay(s) used for follow-up of MPO- and PR3-ANCA patients is illustrated in




**Figure 3:** ANCA testing procedures as reported by the participating laboratories in different European countries. The ANCA testing algorithms (A) include: #1 screening by IIF and if positive testing for both MPO- and PR3-ANCA (\*minimal consensus requirement), #2 screening by IIF and if positive, depending on the pattern, testing for either MPO- or PR3-ANCA, #3 testing all samples by IIF as well as MPO- and PR3-ANCA (\*\*optimal consensus requirement), #4 MPO- and PR3-ANCA without IIF, #5 MPO- and PR3-ANCA and if positive also IIF, #6 other. Panel B represents the availability of STAT ANCA testing; panel C illustrates the possibility to discriminate ANCA requests from the gastroenterology department and to what extent this has consequences for the ANCA testing strategy.

Figure 4. Only very few participating laboratories (<5%) do not perform antigen-specific immunoassays for follow-up, but use IIF testing instead. About 2/3 of the laboratories always use IIF next to the ANCA specificity initially identified. Also, about 1/2 of the laboratories simultaneously test for the reciprocal antibody specificity, i.e. MPO-ANCA in PR3-ANCA patients and *vice versa*. The most striking difference in follow-up between MPO-ANCA and PR3-ANCA patients is related to the way results are presented: qualitative or quantitative. In case of MPO-ANCA

27.7% of the participating laboratories report only qualitative results, while this is 10.1% in case of PR3-ANCA.

ANCA testing is clinically relevant for AAV, but is also used as an adjunct to diagnosis of other disorders, such as gastrointestinal autoimmune diseases. For the latter, performing antigen-specific immuno-assays does not appear to be of added value. Therefore, we surveyed if laboratories are able to discriminate ANCA requests for AAV or for gastro-intestinal autoimmune diseases, and if yes, whether this affected the testing algorithm. Less than



**Figure 4:** Methods used for follow-up of AAV patients with MPO-ANCA (A) or PR3-ANCA (B) as reported by the participating laboratories in different European countries.

Note that laboratories may use more than one method for follow-up; therefore total percentage may exceed 100%.

half of the participating laboratories ( $n=167$ ; 43.4%) are able to determine the clinical background of the ANCA request, i.e. AAV versus gastroenterology (Figure 3C), and only 26.9% ( $n=45$ ) of these laboratories consequently use an alternative algorithm. Large differences are observed between the participating countries.

## Discussion

In the current study we have presented the results of a questionnaire on testing for ANCA in 12 European countries (EASI survey) as compared to the international consensus on ANCA testing [4, 10]. The results reveal major differences between and within countries. In particular with respect to the use of ANCA IIF testing the laboratories participating in the EASI survey often seem to deviate from the international consensus.

The position of the IIF test in the testing algorithm for AAV has been disputed for many years [30–32]. However, assays have changed substantially over the years and recently the results of a multi-center ANCA study on AAV have suggested that screening for ANCA by IIF is not of added value when using a high-quality antigen-specific immuno-assay [26]. Not all tests are the same, however, and performance of each type of assay would need to be validated or verified in laboratories accredited to ISO 15189 and performance continually monitored in external quality assessment schemes. While performance of MPO- and PR3-ANCA immunoassays in AAV diagnosis has been acknowledged, it may not be true for other disorders, such as autoimmune liver diseases and inflammatory bowel disease. It should be kept in mind, though, that some assays for PR3-ANCA commonly reveal low-positive results in ulcerative colitis [33]. Nevertheless, alternative algorithms for use of antigen-specific immunoassays and IIF have been proposed for AAV and non-AAV, respectively [25, 28]. In order to triage samples for alternative testing algorithms sufficient clinical details and laboratory expertise is required, but the results of our study suggest that this is not the case in a substantial number of laboratories.

The clinical relevance of ANCA testing in non-AAV conditions is controversial. Diagnostic criteria for autoimmune hepatitis do not include ANCA in the diagnostic score, as it was not considered helpful [34]. Similarly, the European evidence-based consensus on the diagnosis and management of ulcerative colitis and Crohn's disease stated that the sensitivity of ANCA, in particular P-ANCA, is far from high enough to justify the use of ANCA testing in routine diagnosis [35, 36], and even that the use of

ANCA in combination with other serologic markers such as anti-*Saccharomyces cerevisiae* antibodies (ASCA) is ineffective at differentiating colonic Crohn's disease from ulcerative colitis [36].

The use of alternative IIF fixatives, i.e. formalin and/or methanol, has been proposed to better differentiate between ANCA related to AAV versus other (non-)inflammatory conditions, but there is again no consensus on this issue. The results of the recent multi-center ANCA study have revealed that, as compared to only ethanol-fixed slides, the combination of ethanol- and formalin-fixed slides has a significantly better performance for the diagnosis of AAV [37]. However, in this study ANCA requests from gastroenterology were excluded. The use of formalin- (and methanol)-fixed ANCA slides, however, also has contributed to the many different definitions used for ANCA patterns, in particular for P-ANCA and atypical ANCA (data not shown). Therefore, if the use of alternative IIF fixatives is going to be supported, the terminology used for describing the distinct ANCA patterns should be re-addressed in terms of harmonization.

Rapidly progressive glomerulonephritis and pulmonary alveolar hemorrhage are well recognized as clinical manifestations that require early diagnosis and appropriate treatment. This may be facilitated by STAT ANCA testing. For this purpose special test devices are available in multiple assay formats [19, 22, 38–40]. Nevertheless, this option is not offered to the full extent, i.e. 7 days a week, by the majority of laboratories participating in the EASI survey. The respective clinical manifestations harbor a relatively high pre-test probability of AAV, but the pulmonary-renal syndrome is also associated with anti-GBM disease, also known as Goodpasture's disease [41]. As such, it is important that, in case of STAT ANCA testing, anti-GBM antibodies are analyzed simultaneously, because presence of these antibodies would have impact on the treatment protocol. According to our questionnaire results, inclusion of anti-GBM antibodies is not a standard protocol in about half of the participating laboratories (data not shown).

This study provides an important insight into self-reported practice in ANCA diagnostics internationally and adherence to ANCA consensus guidelines. However, the study has some limitations. The timeframe that was used for distributing the questionnaires in the participating countries was different. While most questionnaires were distributed in 2014 and 2015, this was significantly earlier in the Netherlands (2010). Obviously, the ANCA procedures and assays may have changed over time. The external quality control program in the Netherlands has observed that more laboratories have abandoned ANCA

IIF over time: in 2014 this had increased from 20% to 40% [28]. This is less of an issue in the UK NEQAS programs (W. Egner, personal communication), so caution is required in generalizing, and there are many external influencers for methodological changes. Furthermore, existing methods have been altered by manufacturers in the same period, e.g. FEIA MPO- and PR3-ANCA were changed from a first generation to a third generation test [25]. Identifying all relevant laboratories to survey has been addressed differently in different countries by necessity. This may not have been equally comprehensive. As always in surveys, some laboratories did not answer all questions. Although this was not a major problem, for calculation of percentages the total number of answers provided was taken as 100%. Finally, at the time the questionnaire was developed, i.e. 2009–2010, some newer technologies were not yet widely available and therefore were not included in the answer options. This holds for instance for the CLIA, which appeared to be very prevalent in Italy. However, the consensus guidelines also predate most of the newer technologies and none of these factors would affect ability to adhere to the guidance as long as ELISA is taken to include other antigen-specific immuno-assay variants. Finally, some differences between countries might be explained by national reimbursement policies and national guidelines. For instance, in Belgium testing for antigen-specific immunoassays is only reimbursed as reflex-test following a positive result in the IIF. The prevalence of individual technologies is likely to be affected by country-specific commercial factors as well.

In conclusion, there are apparent differences in ANCA diagnostics within and between countries which affect adherence to international guidelines. Technological changes may have made updating of the guidance necessary to reflect changes since publication.

The major differences observed are about the use of ANCA IIF in the algorithm, the definitions used for P-ANCA and atypical ANCA IIF pattern, the widespread use of newer technologies supplanting ELISA, the lack of availability of STAT testing, and ability to differentiate between requests in the perspective of AAV versus non-AAV, including gastroenterologic diseases. Harmonization of these issues may improve by two ongoing initiatives: (1) the establishment of a new international consensus on ANCA testing, and (2) the introduction of international standards for both MPO- and PR3-ANCA [42].

**Acknowledgments:** Dr. Caroline Roozendaal (University Medical Center Groningen, The Netherlands) is greatly acknowledged for her help in constructing the original questionnaire. Also, all the members of the national

EASI-teams are acknowledged for their collaboration. In Italy EASI is integrated into the Italian Forum on Auto-immune Disease Research (FIRMA). In Switzerland the EASI activities are covered by the Commission of Laboratory Diagnostics of the Swiss Society for Allergology and Immunology (SSAI). In Spain EASI activities are coordinated by the Spanish Group of Autoimmunity (GEAI). Finally, we also thank all the laboratory specialists who returned the completed questionnaire.

**Author contributions:** All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

**Research funding:** None declared.

**Employment of leadership:** None declared.

**Honorarium:** None declared.

**Competing interests:** None declared.

## References

1. Cohen Tervaert JW, Damoiseaux J. Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? *Clin Rev Allergy Immunol* 2012;43:211–9.
2. Radice A, Bianchi L, Sinico RA. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical significance in systemic vasculitis. *Autoimmun Rev* 2013;12:487–95.
3. Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. *Nat Rev Rheumatol* 2014;10:494–501.
4. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). *Am J Clin Pathol* 1999;111:507–13.
5. Choi HK, Liu S, Merkel PA, Colditz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. *J Rheumatol* 2001;28:1584–90.
6. Beauvillain C, Delneste Y, Renier G, Jeannin P, Subra JF, Chevailler A. Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them? *Clin Rev Allergy Immunol* 2008;35:47–58.
7. Kyriakidi KS, Tsianos VE, Karvounis E, Christodoulou DK, Katsanos KH, Tsianos EV. Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases. *Ann Gastroenterol* 2016;29:258–67.
8. Liberal R, Mieli-Vergani G, Vergani D. Clinical significance of autoantibodies in autoimmune hepatitis. *J Autoimmun* 2013;46:17–24.
9. Weiner M, Segelmark M. The clinical presentation and therapy of diseases related to anti-neutrophil cytoplasmic antibodies (ANCA). *Autoimmun Rev* 2016;15:978–82.
10. Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies.

- Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. *Am J Clin Pathol* 2003;120:312–8.
11. Westman KW, Selga D, Bygren P, Segelmark M, Baslund B, Wiik A, et al. Clinical evaluation of a capture ELISA for detection of proteinase-3 antineutrophil cytoplasmic antibody. *Kidney Int* 1998;53:1230–6.
  12. Csernok E, Holle J, Hellmich B, Cohen Tervaert JW, Kallenberg CG, Limburg PC, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. *Rheumatology (Oxford)* 2004;43:174–80.
  13. Hellmich B, Csernok E, Fredenhagen G, Gross WL. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. *Clin Exp Rheumatol* 2007;25 (1 Suppl 44):S1–5.
  14. Damoiseaux J, Dähnrich C, Rosemann A, Probst C, Komorowski L, Stegeman CA, et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. *Ann Rheum Dis* 2009;68:228–33.
  15. Roggenbuck D, Buettner T, Hoffmann L, Schmechta H, Reinhold D, Conrad K. High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. *Ann NY Acad Sci* 2009;1173:41–6.
  16. Damoiseaux J, Vaessen M, Knapen Y, Csernok E, Stegeman CA, Van Paassen P, et al. Evaluation of the FIDIS vasculitis multiplex immunoassay for diagnosis and follow-up of ANCA-associated vasculitis and Goodpasture's disease. *Ann NY Acad Sci* 2007;1109:454–63.
  17. Trevisin M, Pollock W, Dimech W, Savige J. Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD). *J Immunol Methods* 2008;336:104–12.
  18. Kaul R, Johnson K, Scholz H, Marr G. Performance of the BioPlex 2200 Autoimmune Vasculitis kit. *Autoimmun Rev* 2009;8:224–7.
  19. Mahler M, Radice A, Yang W, Bentow C, Seaman A, Bianchi L, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. *Clin Chim Acta* 2012;413:719–26.
  20. Damoiseaux JG, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Tervaert JW. Evaluation of a new fluorescent-enzyme immunoassay for diagnosis and follow-up of ANCA-associated vasculitis. *J Clin Immunol* 2005;25:202–8.
  21. Sinico RA, Radice A, Corace C, Di Toma L, Sabadini E. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis. *Ann NY Acad Sci* 2005;1050:185–92.
  22. Rutgers A, Damoiseaux J, Roozendaal C, Limburg PC, Stegeman CA, Tervaert JW. ANCA-GBM dot-blot: evaluation of an assay in the differential diagnosis of patients presenting with rapidly progressive glomerulonephritis. *J Clin Immunol* 2004;24:435–40.
  23. Damoiseaux J, Steller U, Buschtes M, Vaessen M, Rosemann A, van Paassen P, et al. EUROPLUS ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. *J Immunol Methods* 2009;348:67–73.
  24. Sowa M, Grossmann K, Knütter I, Hiemann R, Röber N, Anderer U, et al. Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. *PLoS One* 2014;9:e107743.
  25. Avery TY, Bons J, van Paassen P, Damoiseaux J. Diagnostic ANCA algorithms in daily clinical practice: evidence, experience, and effectiveness. *Lupus* 2016;25:917–24.
  26. Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paassen P, Baslund B, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. *Ann Rheum Dis* 2017;76:647–53.
  27. Shoenfeld Y, Cervera R, Haass M, Kallenberg C, Khamashta M, Meroni PL, et al. EASI – the European Autoimmunity Standardisation Initiative. *Ann NY Acad Sci* 2007;1109:138–44.
  28. Molen RG van der, Roozendaal C, Damoiseaux JG. Detection of ANCA in Dutch laboratories: clinical practice in relation to the international consensus and national guidelines (In Dutch). *Ned Tijdschr Klin Chem Labgeneesk* 2014;39:19–24.
  29. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. *APMIS Suppl* 1989;6:12–3.
  30. Russel KA, Wiegert E, Schroeder DR, Homburger HA, Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. *Clin Immunol* 2002;103:196–203.
  31. Tervaert JW, Damoiseaux J. Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA? *APMIS Suppl* 2009;127:55–9.
  32. Vermeersch P, Vervaeke S, Blockmans D, Van Hoovels L, Mariën G, Vanmaele H, et al. Determination of anti-neutrophil cytoplasmic antibodies in small vessel vasculitis: comparative analysis of different strategies. *Clin Chim Acta* 2008;397:77–81.
  33. Mahler M, Bogdanos D, Pavlidis P, Fritzler MJ, Csernok E, Damoiseaux J, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. *Clin Chim Acta* 2013;424:267–73.
  34. Lohse AW. Diagnostic criteria for autoimmune hepatitis: scores and more. *Dig Dis* 2015;33 Suppl 2:47–52.
  35. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. *J Crohn's Colitis* 2008;2:1–23.
  36. Assche G van, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. *J Crohn's Colitis* 2010;4:7–27.
  37. Csernok E, Damoiseaux J, Rasmussen N, Hellmich B, van Paassen P, Vermeersch P, et al. Evaluation of automated multiparametric indirect immunofluorescence assays to detect antineutrophil cytoplasmic antibodies (ANCA) in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). *Autoimmun Rev* 2016;15:736–41.
  38. Westman KW, Bygren PG, Eilert I, Wiik A, Wieslander J. Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes. *Nephrol Dial Transplant* 1997;12:1863–8.

39. de Joode AA, Roozendaal C, van der Leij MJ, Bungener LB, Sanders JS, Stegeman CA. Performance of two strategies for urgent ANCA and anti-GBM analysis in vasculitis. *Eur J Intern Med* 2014;25:182–6.
40. Sowa M, Trezzi B, Hiemann R, Schierack P, Grossmann K, Scholz J, et al. Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis. *Medicine (Baltimore)* 2016;95:e5225.
41. Rutgers A, Heeringa P, Damoiseaux JG, Cohen Tervaert JW. ANCA and anti-GBM antibodies in diagnosis and follow-up of vasculitic disease. *Eur J Int Med* 2003;14:287–95.
42. Monogioudi E, Hutu DP, Martos G, Sheldon J, Schimmel H, Meroni PL, et al. Development of a Certified Reference Material for myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA). *Clin Chim Acta* 2017;467:48–50.